Alzheimer’s disease, often referred to as type III diabetes due to its link with insulin resistance, has long been a challenging condition to treat. However, recent research from Italian scientists at the Catholic University of Milan has shown promising results with a nasal spray that targets a key enzyme called S-acyltransferase.
This enzyme, found in excessive amounts in the brains of Alzheimer’s patients, plays a crucial role in attaching fatty acid molecules to beta-amyloid and tau protein clumps. In individuals with brain insulin resistance, this process can spiral out of control, leading to cognitive decline and the accumulation of protein clumps that are characteristic of Alzheimer’s disease.
By disabling the function of S-acyltransferase in mice genetically modified to have an Alzheimer’s-like condition, the researchers were able to slow down neurodegeneration and extend the lifespan of the rodents. Both genetic manipulation and treatment with a nasal spray containing an agent called 2-bromopalmitate showed positive results in reducing Alzheimer’s symptoms.
While 2-bromopalmitate poses risks of interfering with other processes in the body, the researchers are hopeful that alternative agents targeting S-acyltransferase could be developed for safer use in humans. This new approach could potentially lead to better treatments for Alzheimer’s disease, which currently affects a growing number of individuals worldwide.
Further studies will be necessary to determine the safety and efficacy of targeting S-acyltransferase in Alzheimer’s patients. However, with the urgent need for better therapies in the face of a rising number of dementia diagnoses, the research team is committed to exploring new avenues for potential treatments.
The findings of this study, published in the journal PNAS, shed light on the role of S-acyltransferase in Alzheimer’s pathophysiology and highlight it as a potential therapeutic target. As researchers continue to unravel the complexities of this neurodegenerative disease, new approaches like targeting S-acyltransferase offer hope for improved treatments in the future.
